ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – Stock analysts at Zacks Research dropped their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued on Friday, June 23rd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $0.26 for the year, down from their prior estimate of $0.27. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is ($0.56) per share.
Other equities analysts have also issued reports about the stock. Royal Bank of Canada restated an “outperform” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, March 14th. Credit Suisse Group upped their price target on ACADIA Pharmaceuticals from $93.00 to $95.00 in a research report on Friday, April 28th. Bank of America lifted their price objective on ACADIA Pharmaceuticals from $26.00 to $29.00 in a research report on Thursday, June 15th. Guggenheim upped their target price on ACADIA Pharmaceuticals from $22.00 to $25.00 in a report on Tuesday, March 14th. Finally, HC Wainwright lifted their price target on ACADIA Pharmaceuticals from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.29.
ACADIA Pharmaceuticals Stock Up 2.0 %
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). ACADIA Pharmaceuticals had a negative return on equity of 35.70% and a negative net margin of 28.05%. The firm had revenue of $118.46 million during the quarter, compared to analyst estimates of $120.29 million. During the same period in the prior year, the firm earned ($0.70) earnings per share. The business’s revenue was up 2.6% on a year-over-year basis.
Institutional Trading of ACADIA Pharmaceuticals
Several institutional investors have recently modified their holdings of the stock. C M Bidwell & Associates Ltd. acquired a new position in ACADIA Pharmaceuticals during the first quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. lifted its holdings in ACADIA Pharmaceuticals by 33.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 2,198 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 553 shares during the period. CWM LLC boosted its stake in shares of ACADIA Pharmaceuticals by 7,783.3% during the 1st quarter. CWM LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 2,335 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in ACADIA Pharmaceuticals by 169.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in ACADIA Pharmaceuticals during the third quarter worth $60,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.
Insider Activity
In related news, EVP Austin D. Kim sold 1,456 shares of the stock in a transaction dated Thursday, April 6th. The stock was sold at an average price of $18.16, for a total transaction of $26,440.96. Following the transaction, the executive vice president now owns 23,425 shares of the company’s stock, valued at approximately $425,398. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other ACADIA Pharmaceuticals news, EVP Austin D. Kim sold 1,456 shares of the business’s stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $18.16, for a total value of $26,440.96. Following the completion of the transaction, the executive vice president now owns 23,425 shares in the company, valued at $425,398. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 209,053 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were bought at an average price of $25.41 per share, for a total transaction of $5,312,036.73. Following the acquisition, the director now owns 38,811,515 shares in the company, valued at $986,200,596.15. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 67,800 shares of company stock valued at $1,464,879. 27.50% of the stock is currently owned by corporate insiders.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Featured Stories
- Get a free research report on ACADIA Pharmaceuticals from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than ACADIA Pharmaceuticals
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
